Key result
Among 1,644 acute ischemic stroke patients with AF, combined antithrombotic therapy (n=782) was associated with a significantly lower risk of recurrent stroke, SICH, and mortality by day 90.
Why the study?
Does early antithrombotic therapy improve outcomes and reduce recurrent stroke in acute ischaemic stroke patients with atrial fibrillation?
Cohort (n=1,644)
Yes
Does early antithrombotic therapy improve outcomes and reduce recurrent stroke in acute ischaemic stroke patients with atrial fibrillation?
Early introduction of antithrombotics (2-3 days post-stroke) in patients with atrial fibrillation is associated with reduced recurrent stroke and mortality without increasing the risk of symptomatic intracerebral hemorrhage.
Authors
No takes yet. Share an insight, caveat, or question.
May support early combined antithrombotics in acute AF stroke; hypothesis-generating, needs RCT confirmation.
Abdul‐Rahim et al. (2014) conducted a cohort in Acute ischaemic stroke with atrial fibrillation (n=1,644). Combined antithrombotic therapy (anticoagulants and antiplatelets) vs. No antithrombotics was evaluated on Modified Rankin Scale (mRS) outcome and the occurrence of recurrent stroke and symptomatic intracerebral haemorrhage at 90 days. Among 1,644 acute ischemic stroke patients with AF, combined antithrombotic therapy (n=782) was associated with a significantly lower risk of recurrent stroke, SICH, and mortality by day 90.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: